  The Coronavirus Disease (COVID-19) pandemic caused by the SARS-coronavirus 2
(SARS-CoV-2) urgently calls for the design of drugs directed against this new
virus. Given its essential role in proteolytic processing, the main protease
Mpro has been identified as an attractive candidate for drugs against
SARS-CoV-2 and similar coronaviruses. Recent high-throughput screening studies
have identified a set of existing, small-molecule drugs as potent Mpro
inhibitors. Amongst these, Ebselen (2-Phenyl-1,2-benzoselenazol-3-one), a
glutathione peroxidase mimetic seleno-organic compound, is particularly
attractive. Recent experiments suggest that its effectiveness is higher than
that of other molecules that also act at the enzyme catalytic site. By relying
on extensive simulations with all-atom models, in this study we examine at a
molecular level the potential of Ebselen to decrease Mpro catalytic activity.
Our results indicate that Ebselen exhibits a distinct affinity for the
catalytic site cavity of Mpro. In addition, our molecular models reveal a
second, previously unkown binding site for Ebselen in the dimerization region
localized between the II and III domains of the protein. A detailed analysis of
the free energy of binding indicates that the affinity of Ebselen to this
second binding site is in fact significantly larger than that to the catalytic
site. A strain analysis indicates that Ebselen bound between the II-III domains
exerts a pronounced allosteric effect that regulates catalytic site access
through surface loop interactions, and induces a displacement and
reconfiguration of water hotspots, including the catalytic water, which could
interfere with normal enzymatic function. Taken together, these findings
provide a framework for the future design of more potent and specific Mpro
inhibitors, based on the Ebselen scaffold, that could lead to new therapeutic
strategies for COVID-19.
